Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology

Blockade of vascular endothelial growth factor (VEGF) signaling with bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb), or with receptor tyrosine kinase inhibitors, has improved progression-free survival and, in some indications, overall survival across several types of cancers by interru...

Descripción completa

Detalles Bibliográficos
Autores principales: Bannoud, Nadia, Stupirski, Juan C., Cagnoni, Alejandro J., Hockl, Pablo F., Pérez Sáez, Juan M., García, P. Alfredo, Mahmoud, Yamil D., Gambarte Tudela, Julián, Scheidegger, Marco A., Marshall, Andrea, Corrie, Pippa G., Middleton, Mark R., Mariño, Karina V., Girotti, M. Romina, Croci, Diego O., Rabinovich, Gabriel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934167/
https://www.ncbi.nlm.nih.gov/pubmed/36634146
http://dx.doi.org/10.1073/pnas.2214350120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934167/
https://www.ncbi.nlm.nih.gov/pubmed/36634146
http://dx.doi.org/10.1073/pnas.2214350120

Ejemplares similares